Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14004)	7/6/2000 7:49:12 AM
From: Oak Tree	Read Replies (1) \| Respond to of 17367

In the case of LBP however, a little is good a lot is bad. The same is true, but little known, about TNF. Low doses of TNF are a very powerful growth factor, yes growth factor. Its so powerful, that it must have its own feedback loop, and becomes a very powerful killer if the dose increases to even low detectable levels. By this argument, low levels of BPI might be bad and high levels good -- hence the need for 15x or higher. Even however if this is true, it supports my previous statements. This drug is hard to use safely and effectively, the moon and stars have to be in the correct orbit. This is not a robust reliable antimicrobial therapy.

To: Robert K. who wrote (14004)	7/6/2000 12:57:16 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

A little review for newbies>>>>>>>>>>>>>"The science behind NEUPREX®, and the BPI platform for product development, are complementary to our recombinant and vaccines businesses," said Thomas Glanzmann, president, Hyland Immuno. "It serves as an excellent illustration of the strategic growth underway at Hyland Immuno as we diversify our biotechnology portfolio." "We're pleased to have Baxter as our ally," said Jack Castello, chairman, president and CEO of XOMA. "They have excellent worldwide marketing and sales capabilities, particularly in the critical care and emergency hospital market. With Baxter's involvement, we believe we can maximize the value of NEUPREX® by aiming not only for meningococcemia but also for a wide variety of other medical indications." "I am delighted about this relationship with XOMA," said Norbert Riedel, Ph.D., president of Hyland Immuno's Recombinant business. "NEUPREX® addresses an unmet medical need for a critically-ill patient population, and allows Baxter Hyland Immuno the opportunity to bring this product as quickly as possible to the patient and their families who so desperately need it."<<<<<<<<<<<<<<<<<<<<<<<<<